Sign In
Buy CRL
$232.51
-2.11 (-0.90%)
At Close: Jul 31, 2026
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO, Jan. 1, 2026 /PRNewswire/ -- Nati
SAN FRANCISCO, Dec. 31, 2025 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to
SAN FRANCISCO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing SAN FRANCISCO , Dec. 27, 2025 /PRNewswire/ -- National shareholder right
SAN FRANCISCO, Dec. 25, 2025 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO , Dec. 24, 2025 /PRNewswire/ -- Nat
FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug
12:26pm, Wednesday, 24'th Dec 2025
Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.
Corient Private Wealth LLC Raises Holdings in Charles River Laboratories International, Inc. $CRL
03:48am, Wednesday, 24'th Dec 2025
Corient Private Wealth LLC grew its stake in shares of Charles River Laboratories International, Inc. (NYSE: CRL) by 129.3% during the undefined quarter, according to the company in its most recent Fo
SAN FRANCISCO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to
Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?
11:41am, Monday, 22'nd Dec 2025
Are There Red Flags in the Trial Results?
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO , Dec. 22, 2025 /PRNewswire/ -- Na
Assenagon Asset Management S.A. Trims Holdings in Charles River Laboratories International, Inc. $CRL
03:18am, Monday, 22'nd Dec 2025
Assenagon Asset Management S.A. decreased its position in shares of Charles River Laboratories International, Inc. (NYSE: CRL) by 94.4% during the third quarter, according to the company in its most r
Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO , Dec. 19, 2025 /PRNewswire/ -- Nati
SAN FRANCISCO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to
Should You Continue to Hold CRL Stock in Your Portfolio for Now?
09:41am, Thursday, 18'th Dec 2025
Charles River gains from strong RMS demand, strategic partnerships and solid finances but faces macro and competitive pressures in 2025.
